R&D

Pipeline

Ability Pharmaceuticals, SL has investigated the antiproliferative activity in a series of compounds, in in vitro models with several tumor cell lines. The mechanism causing the antiproliferative effect has also been characterized in several candidates.
 
ABTL0812 is currently in phase 2 clinical trials, as first line therapy in patients with endometrial or squamous lung cancer patients.The clinical trial is led by Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Institut Català d’Oncologia (ICO, Hospitalet, Badalona and Girona). The study also includes the INCLIVA (Valencia), Institut Gustave Roussy (Paris), Centre Léon-Bérard (Lyon), Institut Paoli-Calmettes (Marseille) and Hospital Universitario Virgen del Rocío (Sevilla). 

ABTL0812 is an inhibitor of the PI3K/Akt/mTORC signaling pathway with a novel mechanism of action fully differentiated from other PI3K/Akt/mTOR under development or marketed. Cell death is mediated by autophagy.
 

LATEST NEWS

18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016

News

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016

News

Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015

News

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
14.02.2014

News

Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
05.02.2014

News

ABILITY PHARMACEUTICALS Initiates Clinical Trial with its Dual mTORC1/C2 Inhibitor ABTL0812 in Patients with Lung and Pancreatic Cancer + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
Credits